“Weihe Xuesaitong”, a medicine developed by Yunnan Weihe Pharmaceuticals Co. Ltd. for promoting blood circulation, recently passed the US Food and Drug Administration (FDA) examination and approval and has been accepted for clinical trials. This marks the official entry of the medicine into the US market.

“Weihe Xuesaitong” is an oral preparation of Panax Notoginseng Saponins (PNS). It is a purely natural herbal medicine prepared with advanced extraction and purification technologies from Panax notoginseng that are grown in the Wuliang Mountain, where it is free from pollution within a radius of 493 square kilometres. The product can effectively dredge and soften blood vessels and has an anti-thrombotic and anti-stroke effect for patients suffering from cardiovascular diseases, hypertension, hyperglycaemia and hypercholesterolemia. “Weihe Xuesaitong” is the only Chinese pharmaceutical product of its kind to pass the FDA review and access the US market.